21-hydroxylase deficiency overview: Difference between revisions
No edit summary |
|||
| Line 6: | Line 6: | ||
==Overview== | ==Overview== | ||
'''Congenital adrenal hyperplasia due to [[21-hydroxylase]] deficiency''' ('''21-OH CAH'''), in all its forms, accounts for about 95% of diagnosed cases of [[congenital adrenal hyperplasia]], and | '''Congenital adrenal hyperplasia due to [[21-hydroxylase]] deficiency''' ('''21-OH CAH'''), in all its forms, accounts for about 95% of diagnosed cases of [[congenital adrenal hyperplasia]], and '''CAH''' in most contexts refers to 21-hydroxylase deficiency. | ||
==References== | ==References== | ||
Revision as of 16:56, 18 August 2015
|
Congenital adrenal hyperplasia due to 21-hydroxylase deficiency Microchapters |
|
Differentiating Congenital adrenal hyperplasia due to 21-hydroxylase deficiency from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
21-hydroxylase deficiency overview On the Web |
|
American Roentgen Ray Society Images of 21-hydroxylase deficiency overview |
|
Directions to Hospitals Treating Congenital adrenal hyperplasia due to 21-hydroxylase deficiency |
|
Risk calculators and risk factors for 21-hydroxylase deficiency overview |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor-In-Chief: Cafer Zorkun, M.D., Ph.D. [2]
Overview
Congenital adrenal hyperplasia due to 21-hydroxylase deficiency (21-OH CAH), in all its forms, accounts for about 95% of diagnosed cases of congenital adrenal hyperplasia, and CAH in most contexts refers to 21-hydroxylase deficiency.